Skip Ribbon Commands
Skip to main content
Menu

Publications

Prof N Gopalakrishna IYER

  1. Ong CJ, Shannon NB, Mueller S, Lek SM, Qiu X, Chong FT, Li K, Koh KKN, Tay GCA, Skanthakumar T, Hwang JSG, Lim TKH, Ang MK, Tan DSW, Tan NC, Tan HK, Soo KC, Iyer NG. A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer. Oncotarget. 2017 Jun 19. doi: 10.18632/oncotarget.18568. [Epub ahead of print]
  2. See A, Iyer NG, Tan NC, Teo C, Ng J, Soo KC, Tan HK. Distant metastasis as the sole initial manifestation of well-differentiated thyroid carcinoma. Eur Arch Otorhinolaryngol. 2017 Jul;274(7):2877-2882. doi: 10.1007/s00405-017-4532-9. Epub 2017 Apr 5
  3. Ashford BG, Clark J, Gupta R, Iyer NG, Yu B, Ranson M. Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets. Head Neck. 2017 Jul;39(7):1462-1469. doi: 10.1002/hed.24765. Epub 2017 Apr 3.
  4. Wong TH, Skanthakumar T, Nadkarni N, Nguyen HV, Iyer NG. Survival of patients with head and neck squamous cell carcinoma by housing subsidy in a tiered public housing system. Cancer. 2017 Jun 1;123(11):1998-2005. doi: 10.1002/cncr.30557. Epub 2017 Jan 30
  5. Jang JH, Tan HK, Iyer NG, Soo KC, Tan NC. Nasopharyngectomy with operating microscope: A case series. Am J Otolaryngol. 2017 Jan - Feb;38(1):82-86. doi: 10.1016/j.amjoto.2016.07.008. Epub 2016 Sep 25.
  6. Ng JH, Iyer NG, Tan MH, Edgren G. Changing epidemiology of oral squamous cell carcinoma of the tongue: A global study. Head Neck. 2017 Feb;39(2):297-304. doi: 10.1002/hed.24589. Epub 2016 Oct 3
  7. Tian B, Iyer NG, Tan HK, Tay AC, Soo KC, Tan NC. Novel technique of creating a seal for the vacuum-assisted closure system application in complex head and neck wounds. Head Neck. 2016 Dec; 38(12):E2523-E2526. doi: 10.1002/hed.24563. Epub 2016 Aug 18.

Professor Pierce Chow

Selected publications of the last 5 years:

  1. Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh BKP, Albani S, Chow PKH, Zhai W, Chew V. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun., 12(1):227. https://doi.org/10.1038/s41467-020-20171-7. PMID: 33431814.
  2. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. (2021) Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. https://doi.org/10.1159/000514400
  3. Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY, Chow PKH, Ginhoux F, DasGupta R. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 183(2):377-394.e21. https://doi.org/10.1016/j.cell.2020.08.040. PMID: 32976798
  4. Ding, Z., Ericksen, R, Escande-Beillard, N., Lee, Q.Y, Loh A., Denil, S., Steckel, M., Andrea Haegebarth, A., Ho, S.W., Chow, P.K., Toh, H.C., Reversade, B., Gruenewald, S., Han, W. (2020) Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J. Hepatol., 72(4):725-35, ISSN 0168-8278, https://doi.org/10.1016/j.jhep.2019.10.026
  5. Hack, S. P., Spahn, J., Chen, M., Cheng, A. L., Kaseb, A., Kudo, M., Lee, H. C., Yopp, A., Chow, P., & Qin, S. (2020). IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol., 16(15):975-89. https://doi.org/10.2217/fon-2020-0162
  6. Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK, Han W. (2020) Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol. Commun., 4(9):1362-81. https://doi.org/10.1002/hep4.1559.
  7. Jin, Y., Wong, Y.S., Goh, B.K.P., Chan, C.Y., Cheow, P.C., Chow, P.K.H., Lim, T.K.H., Goh, G.B.B., Krishnamoorthy, T.L., Kumar, R., Ng, T.P., Chong, S.S., Tan, H.H., Chung, A.Y.F, Ooi, L.L., Chang, J.P.E., Tan, C.K., and Lee, C.G.L. (2019) Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci. Rep., 9(10464). https://doi.org/10.1038/s41598-019-46872-8
  8. Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai, L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng, D., Filarca, R.L.F, Albani, S., and Chow, P.K.H. (2018). Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485. https://doi.org/10.1136/gutjnl-2017-315485.
  9. Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T.K.H., Yeong, J., Toh, H.C., Lee, S.Y., Chan, C.Y., Goh, B.K., Chung, A., Heikenwalder, M., Ng, I.O., Chow, P., Albani, S., and Chew, V. (2018). Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut. https://doi.org/10.1136/gutjnl-2018-316510.
  10. Zhao, Y., Shuen, T.W.H., Toh, T.B., Chan, X.Y., Liu, M., Tan, S.Y., Fan, Y., Yang, H., Lyer, S.G., Bonney, G.K., Loh, E., Chang, K.T.E., Tan, T.C., Zhai, W., Chan, J.K.Y., Chow, E.K., Chee, C.E., Lee, G.H., Dan, Y.Y., Chow, P.K., Toh, H.C., Lim, S.G., and Chen, Q. (2018). Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment and Immunotherapy. Gut. pii: gutjnl-2017-315201. https://doi.org/10.1136/gutjnl-2017-315201.
  11. Pierce K.H. Chow, Mihir Gandhi, Say-Beng Tan, et al. (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J. Clin. Oncol., JCO2017760892. https://doi.org/10.1200/JCO.2017.76.0892.
  12. Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP, Khor CC, Soon WW, Sung KW, Foo RS, Chow PK (2017) The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8:4565. https://doi.org/10.1038/ncomms14565
  13. Huynh, H., Lee, L.Y., Goh, K.Y., Ong, R., Hao, H.X., Huang, A., Wang, Y., Graus, P.D., Chow, P., and Chung, A. (2019). Infigratinib mediates vascular normalization, impairs metastasis, and improves chemotherapy in hepatocellular carcinoma. Hepatology 69(3):943-58. https://doi.org/10.1002/hep.30481.
  14. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V (2017) Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 66(2):342-51. https://doi.org/1010.1136/gutjnl-2015-310814
  15. Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V (2017) VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res. Protoc. 6(2):17. https://doi.org/1010.2196/resprot.7016.
  16. Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK (2016) Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 16(1):856. https://doi.org/10.1186/s12885-016-2868-y

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT)

  1. Gwee YX, Chia DKA, So J, Yong WP, Tan P, Ong C-AJ*, Sundar R* (2022) Integration of genomic biology into therapeutic strategies of gastric cancer. J Clin Oncol JCO2102745 (* Co-corresponding authors)
  2. Hendrikson J*, Liu Y*, Ng WH, Lee JY, Lim AH, Loh JW, Ng CCY, Ong WS, Tan JWS, Tan QX, Ng G, Shannon NB, Lim WK, Lim TKH, Chua C, Wong JSM, Tan GHC, So JBY, Yeoh KG, Teh BT, Chia CS, Soo KC, Kon OL, Tan IBH, Chan JY, Teo MCC, Ong C-AJ, Singapore Peritoneal Oncology Study (SPOS) Group and Singapore Gastric Cancer Consortium (SGCC) (2022) Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. Cell Rep Med 3(2): 100526 (* Equal contribution)
  3. Wong JSM*, Lek SM*, Lim YZD, Chia CS, Tan GHC, Ong C-AJ, Teo MCC (2022) Palliative Gastro-intestinal Surgery in Patients with Advanced Peritoneal Carcinomatosis: Clinical Experience and Development of a Predictive Model for Surgical Outcomes. Front Oncol11: 811743 (* Equal contribution)
  4. Wong LCK*, Li Z*, Qiao F, Tan JWS, Tan QX, Wong JSM, Ong C-AJ, Chia CS (2022) Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis – A systematic review and meta-analysis. Eur J Surg Oncol 48(3): 640-648 (* Equal contribution)
  5. Yap DRY*, Wong JSM*, Tan QX, Tan JWS, Chia CS, Ong C-AJ (2021) Effect of HIPEC on peritoneal recurrence in peritoneal metastasis treated with cytoreductive surgery: a systematic review. Front Oncol11: 795390 (* Equal contribution)
  6. Ong XYS, Sultana R, Tan JWS, Tan QX, Wong JSM, Chia CS, Ong CAJ (2021) The role of total parenteral nutrition in patients with peritoneal carcinomatosis: a systematic review and meta-analysis. Cancers (Basel)  13(16): 1456
  7. Shannon NB*, Tan LLY*, Tan QX, Tan JWS, Hendrikson J, Ng WH, Ng G, Liu Y, Ong XYS, Nadarajah R, Wong JSM, Tan GHC, Soo KC, Teo MCC, Chia CS, Ong C-AJ (2021) A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer. Sci Rep11: 16829 (* Equal contribution)
  8. Moon EW, Wong JSM, See AHM, Ong WS, Tan CA, Ong CAJ, Chia CS, Soo KC, Teo MCC, Tan GHC (2021) Predicting early and late readmissions following cytoreductive surgery & hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol doi: 10.1245/s10434-021-10414-2
  9. Shannon NB*, Tan QX*, Tan JWS, Hendrikson J, Ng WH, Ng G, Liu Y, Tan GHC, Wong JSM, Soo KC, Teo MCC, Chia CS, Ong CAJ (2021) Gene expression changes associated with dedifferentiation in liposarcoma predict overall survival. Cancers (Basel)13: 3049 (* Equal contribution)
  10. Wang Z, Zhao H, Zhang Y, Natalia A, Ong CAJ, Teo MCC, So JBY, Shao H (2021) Surfactant-guided spatial assembly of nano-architecture for molecular profiling of extracellular vesicles. Nat Commun12(1): 4039
  11. Chan J, Tan GF, Yeong J, Ong CW, Ng DYX, Lee E, Koh J, Ng CC-Y, Lee JY, Liu W, Wong RX, Ong C-AJ, Farid M, Teh BT, Soo KC (2021) Clinical implications of systemic and local immune responses in human angiosarcoma. npj Precision Oncology5(1):11
  12. Thiagarajan S*, Tan JWS*, Zhou S, Tan QX, Hendrikson J, Ng WH, Ng G, Tan GHC, Soo KC, Teo MCC, Chia CS, Ong C-AJ (2021) Postoperative inflammatory marker surveillance in colorectal peritoneal carcinomatosis. Ann Surg Oncol28(11): 6625-6635
  13. Ong C-AJ*, Lim HJ*, Tan JWS, Wong JSM, Lim ST, Kwek JW, Tan HK, Hwang WYK, Chia CS (2020) Facilitating timely cancer care in a surgical oncology subspecialty unit during the pandemic and recovery phase of the COVID era. Asian J Surg43(9): 965-966
  14. Wu X, Zhao H, Natalia A, Lim CZJ, Ho NRY, Ong C-AJ, Teo MCC, So JBY, Shao H (2020) Exosome-templated nanoplasmonics for multiparametric molecular profiling. Sci Adv6(19): eaba2556
  15. Ong CAJ*, Tan QX*, Lim HJ*, Shannon NB, Lim WK, Hendrikson J, Ng WH, Tan JWS, Koh KKN, Wasudevan SD, Ng CCY, Rajasegaran V, Lim TKH, Ong CK, Kon OL, Teh BT, Tan GHC, Chia CS, Soo KC, Teo MCC (2020) An optimised protocol harnessing laser capture microdissection on matched primary and metastatic colorectal tumours. Sci Rep10:682 (* Equal contribution)

DSSO Breast Team:

  1. Ho PJ, Khng AJ, Tan BK, Tan EY, Tan SM, Tan VKM, Lim GH, Aronson KJ, Chan TL, Choi JY, Dennis J, Ho WK, Hou MF, Ito H, Iwasaki M, John EM, Kang D, Kim SW, Kurian AW, Kwong A, Lophatananon A, Matsuo K, Mohd-Taib NA, Muir K, Murphy RA, Park SK, Shen CY, Shu XO, Teo SH, Wang Q, Yamaji T, Zheng W, Bolla MK, Dunning AM, Easton DF, Pharoah PDP, Hartman M, Li J. Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer. 2022 May 11. doi: 10.1007/s12282-022-01366-w. Epub ahead of print. PMID: 35543923.
  2. Yit LFN, Quek SZH, Wong FY, Tan PH, Tan B, Sim Y, Tan BF, Wong RX, Tan TJY. 203P Curative treatment outcomes in metaplastic breast cancer. Ann Oncol. 2022 May; 33(Suppl 3):S220 doi.org/10.1016/j.annonc.2022.03.222
  3. Ang BH, Ho WK, Wijaya E, Kwan PY, Ng PS, Yoon SY, Hasan SN, Lim JMC, Hassan T, Tai MC, Allen J, Lee A, Taib NAM, Yip CH, Hartman M, Lim SH, Tan EY, Tan BKT, Tan SM, Tan VKM, Ho PJ, Khng AJ, Dunning AM, Li J, Easton DF, Antoniou AC, Teo SH. Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer. J Clin Oncol. 2022 May 10;40(14):1542-1551. doi: 10.1200/JCO.21.01647. Epub 2022 Feb 10. PMID: 35143328.
  4. Lim JT, Koh JJE, Ho PJ, Liu J, Lim SH, Tan EY, Tan BKT, Tan VKM, Tan SM, Yong WS, Hartman M, Chen C. Impact of Subsidy on the Use of Personalized Medicine in Breast Cancer. Value Health Reg Issues. 2022 May;29:108-115. doi: 10.1016/j.vhri.2021.10.002. Epub 2022 Jan 29. PMID: 35104748.
  5. Ng PS, Boonen RA, Wijaya E, Chong CE, Sharma M, Knaup S, Mariapun S, Ho WK, Lim J, Yoon SY, Mohd Taib NA, See MH, Li J, Lim SH, Tan EY, Tan BK, Tan SM, Tan VK, van Dam RM, Rahmat K, Yip CH, Carvalho S, Luccarini C, Baynes C, Dunning AM, Antoniou A, van Attikum H, Easton DF, Hartman M, Teo SH. Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore. J Med Genet. 2022 May;59(5):481-491. doi: 10.1136/jmedgenet-2020-107471. Epub 2021 Apr 2. PMID: 33811135.
  6. Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR; Ai3. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat. 2022 May;193(1):121-138. doi: 10.1007/s10549-022-06521-7. Epub 2022 Mar 9. PMID: 35262831.
  7. Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK, Tan EY, Lim GH, Tan SM, Tan VKM, Yip CH, Mohd-Taib NA, Wong FY, Lim EH, Ngeow J, Chay WY, Leong LCH, Yong WS, Seah CM, Tang SW, Ng CWQ, Yan Z, Lee JA, Rahmat K, Islam T, Hassan T, Tai MC, Khor CC, Yuan JM, Koh WP, Sim X, Dunning AM, Bolla MK, Antoniou AC, Teo SH, Li J, Hartman M. Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Med. 2022 Apr 26;20(1):150. doi: 10.1186/s12916-022-02334-z. PMID: 35468796; PMCID: PMC9040206.
  8. Lim JSH, Sim Y, Ngeow J, Yuen J, Tan VKM, Tan BKT, Yong WS, Wong CY, Lim SZ, Hamzah JLB, Tan SY, Wong FY, Madhukumar P. Male breast cancer: a Singapore perspective. ANZ J Surg. 2022 Apr 25. doi: 10.1111/ans.17737. Epub ahead of print. PMID: 35470542.
  9. Ng DYX, Li Z, Lee E, Kok JST, Lee JY, Koh J, Ng CC, Lim AH, Liu W, Ng SR, Lim KS, Huang XX, Hong JH, Guan P, Sim Y, Thike AA, Nasir NDM, Li S, Tan PH, Teh BT, Chan JY. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022 Apr 1;8(1):44. doi: 10.1038/s41523-022-00413-1. PMID: 35365682; PMCID: PMC8975864.
  10. Sim Y, Lim C, Phyu N, Tan KTB, Chew LST, Wong CY, Madhukumar P, Yong WS, Lim SZ, Hamzah JLB, Tan SY, Chay WY, Wong FY, Tan PH, Tan VK. The Impact of Statin Use and Breast Cancer Recurrence - A Retrospective Study in Singapore. Front Oncol. 2022 Mar 31;12:835320. doi: 10.3389/fonc.2022.835320. PMID: 35433431; PMCID: PMC9008885.
  11. Lim ZL, Lim GH, Ho PJ, Khng AJ, Yeoh YS, Ong ATW, Tan BKT, Tan EY, Tan SM, Tan VK, Li J, Hartman M. Associations between Pre-Diagnostic Physical Activity with Breast Cancer Characteristics and Survival. Cancers (Basel). 2022 Mar 30;14(7):1756. doi: 10.3390/cancers14071756. PMID: 35406528; PMCID: PMC8997033.
  12. Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. PMID: 35296300; PMCID: PMC8928638.
  13. Yap DWT, Tan NKW, Tan BKJ, Teo YH, Tan VKM, See A, Toh ST. The Association of Obstructive Sleep Apnea With Breast Cancer Incidence and Mortality: A Systematic Review and Meta-analysis. J Breast Cancer. 2022 Mar 10. doi: 10.4048/jbc.2022.25.e11. Epub ahead of print. PMID: 35380020.
  14. Ho WK, Tai MC, Dennis J, Shu X, Li J, Ho PJ, Millwood IY, Lin K, Jee YH, Lee SH, Mavaddat N, Bolla MK, Wang Q, Michailidou K, Long J, Wijaya EA, Hassan T, Rahmat K, Tan VKM, Tan BKT, Tan SM, Tan EY, Lim SH, Gao YT, Zheng Y, Kang D, Choi JY, Han W, Lee HB, Kubo M, Okada Y, Namba S; BioBank Japan Project, Park SK, Kim SW, Shen CY, Wu PE, Park B, Muir KR, Lophatananon A, Wu AH, Tseng CC, Matsuo K, Ito H, Kwong A, Chan TL, John EM, Kurian AW, Iwasaki M, Yamaji T, Kweon SS, Aronson KJ, Murphy RA, Koh WP, Khor CC, Yuan JM, Dorajoo R, Walters RG, Chen Z, Li L, Lv J, Jung KJ, Kraft P, Pharoah PDB, Dunning AM, Simard J, Shu XO, Yip CH, Taib NAM, Antoniou AC, Zheng W, Hartman M, Easton DF, Teo SH. Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genet Med. 2022 Mar;24(3):586-600. doi: 10.1016/j.gim.2021.11.008. Epub 2021 Dec 15. PMID: 34906514; PMCID: PMC7612481.
  15. Bong TSH, Tan JKT, Ho JTS, Tan PH, Lau WS, Tan TM, Wong JSL, Tan VKM, Tan BKT, Madhukumar P, Yong WS, Lim SZ, Wong CY, Ong KW, Sim Y. Atypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade on Surgical Excision. J Breast Cancer. 2022 Feb;25(1):37-48. doi: 10.4048/jbc.2022.25.e7. PMID: 35199500; PMCID: PMC8876544.
  16. Chiam M, Ho CY, Quah E, Chua KZY, Ng CWH, Lim EG, Tan JRM, Wong RSM, Ong YT, Soong YL, Kwek JW, Yong WS, Loh KWJ, Lim C, Mason S, Krishna LKR. Changing self-concept in the time of COVID-19: a close look at physician reflections on social media. Philos Ethics Humanit Med. 2022 Jan 26;17(1):1. doi: 10.1186/s13010-021-00113-x. PMID: 35078488; PMCID: PMC8789479.
  17. Linn YL, Tay TKY, Tan EH, Wong JSL, Madhukumar P. Breast metastasis presenting as swelling with calcification - A case report and review of the literature. Breast Dis. 2022;41(1):151-154. doi: 10.3233/BD-210035. PMID: 35068435.
  18. Choo PZQ, Loh AHL, Selvarajan S, Tan PH, Tan VKM, Yong WS, Leong LCH. Breast-related extranodal Rosai-Dorfman disease presenting as subcutaneous masses with thick hyperechoic rim, with review of the literature. Breast J. 2021 Dec;27(12):883-886. doi: 10.1111/tbj.14286. Epub 2021 Aug 31. PMID: 34467595.
  19. Ho PJ, Khng AJ, Loh HW, Ho WK, Yip CH, Mohd-Taib NA, Tan VKM, Tan BK, Tan SM, Tan EY, Lim SH, Jamaris S, Sim Y, Wong FY, Ngeow J, Lim EH, Tai MC, Wijaya EA, Lee SC, Chan CW, Buhari SA, Chan PMY, Chen JJC, Seah JCM, Lee WP, Mok CW, Lim GH, Woo E, Kim SW, Lee JW, Lee MH, Park SK, Dunning AM, Easton DF, Schmidt MK, Teo SH, Li J, Hartman M. Germline breast cancer susceptibility genes, tumor characteristics, and survival. Genome Med. 2021 Dec 2;13(1):185. doi: 10.1186/s13073-021-00978-9. PMID: 34857041; PMCID: PMC8638193.
  20. Lim CHS, Leong LCH, Lim SZ, Su MN, Moey THL, Tay KYT, Tan PH. Bone in the breast: Clinical, radiological and pathological correlation. Ann Acad Med Singap. 2021 Oct;50(10):798-801. doi: 10.47102/annals-acadmedsg.2020611.
  21. Loo SY, Toh LP, Xie WH, Pathak E, Tan W, Ma S, Lee MY, Shatishwaran S, Yeo JZZ, Yuan J, Ho YY, Peh EKL, Muniandy M, Torta F, Chan J, Tan TJ, Sim Y, Tan V, Tan B, Madhukumar P, Yong WS, Ong KW, Wong CY, Tan PH, Yap YS, Deng LW, Dent R, Foo R, Wenk MR, Lee SC, Ho YS, Lim EH, Tam WL. Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Sci Adv. 2021 Oct 8;7(41):eabh2443. doi: 10.1126/sciadv.abh2443. Epub 2021 Oct 6.
  22. Lim SZ, Kusumawidjaja G, Mohd Ishak HM, Tan BKT, Tan SY, Hamzah JL, Madhukumar P, Yong WS, Wong CY, Sim Y, Lim GH, Lim SH, Tan SM, Wong FY, Tan VKM. Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy. Breast Cancer Res Treat. 2021 Oct;189(3):837-843. doi: 10.1007/s10549-021-06341-1. Epub 2021 Aug 3. PMID: 34342766.
  23. Ho PJ, Dorajoo R, Ivanković I, Ong SS, Khng AJ, Tan BK, Tan VKM, Lim SH, Tan EY, Tan SM, Tan QT, Yan Z, Ngeow J, Sim Y, Chan P, Chuan JCJ, Chan CW, Tang SW, Hartman M, Li J. DNA methylation and breast cancer-associated variants. Breast Cancer Res Treat. 2021 Aug;188(3):713-727. doi: 10.1007/s10549-021-06185-9. Epub 2021 Mar 26. PMID: 33768416.
  24. Ng CCY, Md Nasir ND, Loke BN, Tay TKY, Thike AA, Rajasegaran V, Liu W, Lee JY, Guan P, Lim AH, Chang KTE, Gudi MA, Madhukumar P, Tan BKT, Tan VKM, Wong CY, Yong WS, Ho GH, Ong KW; International Fibroepithelial Consortium, Yip GWC, Bay BH, Tan P, Teh BT, Tan PH. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing. Mod Pathol. 2021 Jul;34(7):1320-1332. doi: 10.1038/s41379-021-00787-w. Epub 2021 Mar 16. PMID: 33727697.
  25. Tan NKW, Yap D, Tan BKJ, Teo YH, Tan VKM, See A, Toh ST. 158P Obstructive sleep apnea and breast cancer incidence: A systematic review and meta-analysis. Ann Oncol. 2021 May; 32(Suppl 2):S89 doi.org/10.1016/j.annonc.2021.03.172
  26. Ong SS, Ho PJ, Khng AJ, Lim GH, Lim SH, Ow SGW, Pang JS, Tan BKT, Tan EY, Tan SM, Tan VKM, Wong FY, Hartmann. 31P Association between breast cancer protein truncating variants and febrile neutropenia breast cancer patients treated with taxane or anthracycline chemotherapy in Singapore. Ann Oncol. 2021 May; 32(Suppl 2):S33 doi.org/10.1016/j.annonc.2021.03.045
  27. Ishak HMM, Nitar P, Wong FY, Kusumawidjaja G, Leong L, Sim Y, Hakim M, Chay WY, Wong RX. Association of blood inflammatory/immune markers with outcomes in (neo)adjuvant breast cancer: A large single institutional study. J Clin Oncol. 2021 May; 39(15_Suppl):e12540 doi.org/10.1200/JCO.2021.39.15_suppl.e12540
  28. Zou R, Loke SY, Tan VK, Quek ST, Jagmohan P, Tang YC, Madhukumar P, Tan BK, Yong WS, Sim Y, Lim SZ, Png E, Lee SYS, Chan MYP, Ho TSJ, Khoo BKJ, Wong SLJ, Thng CH, Chong BK, Teo YY, Too HP, Hartman M, Tan NC, Tan EY, Lee SC, Zhou L, Lee ASG. Development of a microRNA Panel for Classification of Abnormal Mammograms for Breast Cancer. Cancers (Basel). 2021 Apr 28;13(9):2130. doi: 10.3390/cancers13092130. PMID: 33925125; PMCID: PMC8124944.
  29. Ho PJ, Yeoh YS, Miao H, Lim SH, Tan EY, Tan BKT, Tan VKM, Tan SM, Yong WS, Wong FY, Madhukumar P, Chan CW, Iau PTC, Lee SC, Putti T, Buhari SA, Lee JY, Lim GH, Woo E, Yan Z, Chan PMY, Chen JJC, Lu SQ, Dent R, Lee WP, Mok CW, Seah JCM, Sim X, van Dam RM, Chia KS, Li J, Hartman M. Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers. PLoS One. 2021 Apr 26;16(4):e0250102. doi: 10.1371/journal.pone.0250102. PMID: 33901219; PMCID: PMC8075208.
  30. Asano M, Koh GC, Madhukumar P, Teng GYH, Liew PLL, Nagalingam S, Tan MLM, Ng YS, Tan BKT. Study protocol: a pilot quasi-experimental trial of tele-rehabilitation and tele-drain care post-mastectomy. Pilot Feasibility Stud. 2021 Feb 1;7(1):39. doi: 10.1186/s40814-021-00776-5. PMID: 33522962; PMCID: PMC7849141.